Federal task force moves to favor HPV tests over Pap smears for cervical cancer screening
The not-yet-final change would also let women ages 30 to 65 collect their own samples, which could shift how millions are screened and what insurers must cover.

Key Takeaways
- Women 30 to 65 would be steered toward an HPV test instead of a Pap smear, with self-collection allowed
- Pap tests every three years would remain the advice for women 21 to 29
- The panel also clarified who can stop screening at 65
- When, or whether, the change becomes final is unclear, including whether Health Secretary Robert F. Kennedy Jr. will weigh in
The U.S. Preventive Services Task Force has voted to recommend an HPV test, rather than the decades-old Pap smear, as the preferred cervical cancer screening for women ages 30 to 65, NBC News reported, citing a person familiar with the vote. Women in that age group would also be able to swab themselves instead of undergoing a speculum exam.
The recommendation is not yet final. According to NBC's source, panel members voted privately Friday as a two-day meeting wrapped up. A task force spokesperson did not respond to NBC's request for comment, and a Department of Health and Human Services spokesperson did not immediately respond.
If it holds, this would be the first time federal guidance steers women toward HPV testing over the Pap, and it is the right call on the evidence. The bigger question is whether it survives a review process that has grown less predictable.
What would change for patients
Under the task force's previous guidance, women 30 to 65 could pick one of three paths: a Pap test every three years, an HPV test every five years, or both together every five years. The new recommendation would tilt that choice decisively toward HPV testing and add a self-collected sample as an option.
Younger women would see no change. The panel still recommends a Pap test every three years for women 21 to 29.
The task force also spelled out who should stop screening at 65. Women can stop only if they have had several negative results in a row over the past 10 years, according to the panel. Those without that track record should keep getting screened. That clarification matters more than it sounds: many women have gaps in their screening history, and a vague age cutoff invites them to stop too early.
The money side is what gives the panel its power. Under the Affordable Care Act, most private insurers generally must cover services the task force recommends without charging patients. A formal endorsement of self-collected HPV tests would put that option on firmer footing for coverage.
Why the HPV test wins on evidence
The two tests look for different things. A Pap test examines cervical cells for abnormal or precancerous changes. An HPV test checks for high-risk strains of human papillomavirus, the virus responsible for virtually all cervical cancers and the most common sexually transmitted infection in the country. Because the virus can usually be detected before cells start to change, a negative HPV result supports a longer wait before the next test.
A 2018 study in the Journal of the American Medical Association, which included more than 19,000 women, found that HPV testing caught precancerous cervical changes earlier and more accurately than Pap testing.
Dr. Sangini Sheth, an associate professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine, said a Pap test alone catches only roughly 50% to 70% of abnormalities. Many women receive both tests together, but she said most of the benefit comes from the HPV portion, and women who skip HPV testing are much more likely to have a virus-related problem slip through.
"There's really not a downside to not having that Pap," Sheth said.
That is a striking thing to hear about a test that has been the backbone of cervical screening for generations. But it reflects where the science has been heading for years, and the task force is catching up rather than leading.
The case for self-collection
The self-swab option may end up mattering more than the switch in test type. A self-collected HPV sample uses a simple vaginal swab and skips the speculum, which experts say makes it generally more comfortable.
Robert Smith, a cancer epidemiologist and senior vice president of early cancer detection science at the American Cancer Society, said discomfort leads some women to delay Pap tests, particularly when a male doctor performs the exam. He said he expects self-collection to increase screening, and he dismissed concerns about reliability.
"Collecting a specimen is pretty easily accomplished and it really has equivalent accuracy with a physician-collected specimen," Smith said.
Sheth said self-collection could help patients who struggle with a speculum exam and could move screening into new settings, such as mobile health clinics, freestanding labs and specialty medical offices that don't normally do pelvic exams.
That expansion is the real opportunity here. Cervical cancer is among the most preventable cancers, yet recent research suggests the U.S. is slipping in catching it early. A test that doesn't require a gynecology appointment attacks one of the most common reasons people fall behind.
Gaps with other guidelines and an uncertain path
The vote moves the task force closer to the American Cancer Society, which began prioritizing HPV testing in 2020. Differences remain. The cancer society advises starting screening at 25 with an HPV test, while the task force keeps Pap tests from 21 and switches to HPV testing at 30. For self-collected samples, the cancer society recommends testing every three years rather than five, because it wants more long-term data before endorsing a longer interval, Smith said.
Those mismatches are small on paper but could confuse patients who hear one interval from a doctor and another from a cancer charity. The three-year caution on self-swabs is reasonable while long-term data accumulates, and it would be useful for the two groups to converge as that data arrives.
The American College of Obstetricians and Gynecologists said in a statement that it is monitoring the process and "will evaluate the final proposed changes when available."
Timing is the larger unknown. Task force recommendations are typically final once published, and no publication date has been announced. It is also unclear whether Health Secretary Robert F. Kennedy Jr. will need to approve the change or will seek to alter it. A court ruling last year confirmed that the health secretary has authority over the panel, upholding the panel's legitimacy because the secretary can remove members and review their recommendations. That case was brought by a Christian-owned business that objected to covering an HIV prevention drug.
In September, Kennedy named eight new members to the panel. The New York Times reported that documents show some own stock in companies making drugs and other products affected by the group's decisions; NBC News said it had not independently reviewed those documents. This week's meeting was the panel's first in more than a year.
The recommendation itself is well grounded in the data. Until it is published, though, women and their doctors are working from the old menu of options, and insurers are under no new obligation to cover a self-collected test.




